Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation

Petruskevicius, Irma; Ludvigsen, Maja; Hjortebjerg, Rikke; Sørensen, B.; Kamper, Peter; Vase, Maja Ølholm; Oestgaard, L G; Nielsen, Bendt; Honoré, Bent; Bjerre, Mette; Rabinovich, Gabriel A.; d’Amore, Francesco

doi:10.1038/bmt.2016.127

Cited by 2 publications

(3 citation statements)

References 14 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, for 24 patients, we were able to measure serum Gal-1 in a sample taken 3 months after HDT. Data from a previously published study in which we have measured serum Gal-1 in 30 healthy donors were included as a control group: 53% male, median age 53 years (range 45–66 years) 10. All samples were stored at −80°C.…”

Section: Methodsmentioning

confidence: 99%

“…Serum Gal-1 levels were measured using a time-resolved immunofluorometric assay as described previously 10. Microtiter wells were coated with capture antibody (AF1152, R&D Systems) at 2 μg/mL in phosphate-buffered saline (PBS)/pH 8 for 2 h. Plates were washed and blocked for 1 h (PBS, pH 7.4, 1% [v/v] Tween20).…”

Section: Methodsmentioning

confidence: 99%

“…Gal-1 can be secreted from cells by an unknown mechanism1 and can be measured in blood samples 9,10. In patients with chronic lymphocytic leukemia (CLL), both bone marrow and plasma levels of Gal-1 were increased in patients with progressive compared with stable disease, and CLL-supporting myeloid cells were found to be the major producers of Gal-1 11.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation

Andersen¹,

Ludvigsen²,

Abildgaard³

et al. 2017

OTT

View full text Add to dashboard Cite

Galectin-1 (Gal-1) is known to regulate cell signaling within the immune system and may be a target for new anticancer immune therapy. In patients with chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL), high levels of Gal-1 within the tumor microenvironment were associated with worse disease state or poor outcome. Gal-1 can be secreted from cells by an unknown mechanism, and levels in blood samples were associated with high tumor burden and worse disease state in cHL and CLL patients. However, serum levels of Gal-1 have never been investigated in patients with multiple myeloma (MM). We measured serum Gal-1 levels in samples from patients with treatment demanding MM at the time of diagnosis (n=102) and after treatment (n=24) and examined associations of serum Gal-1 with clinicopathological information obtained from patient medical records, as well as data on bone marrow angiogenesis and the macrophage activation biomarkers soluble CD163 (sCD163) and soluble mannose receptor. Serum Gal-1 levels were not elevated in patients with MM at diagnosis compared with healthy donors (median values 8.48 vs 11.93 ng/mL, P=0.05), which is in contrast to results in cHL and CLL. Furthermore, Gal-1 levels did not show association with bone marrow angiogenesis, clinicopathological parameters, overall survival, or response to treatment. There was a statically significant association between Gal-1 and sCD163 levels (R=0.24, P=0.02), but not with soluble mannose receptor (P=0.92). In conclusion, our results indicate that Gal-1 is not an important serum biomarker in MM, which is in contrast to data from patients with cHL and CLL. However, the association with sCD163 is in line with previous data showing that Gal-1 may be involved in alternative (M2-like) activation of macrophages.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%